Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial

What Was Tested

This randomized controlled trial paper looks at Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism.

The primary aim is to evaluate the effects of the mineralocorticoid receptor antagonist eplerenone on plasma intact PTH (iPTH) concentration in patients with pHPT.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

The Eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism (EPATH) trial is a single-center, randomized, double-blind, parallel-group, placebo-controlled trial.

Secondary end points comprised surrogate parameters of cardiovascular health [24-h ambulatory SBP and DBP and echocardiographic parameters related to systolic/diastolic function as well as to cardiac dimensions].

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Parathyroid Hormone (PTH 1-84).

The comparison arm used a placebo, so changes seen with Parathyroid Hormone (PTH 1-84) could be set against what happens without it.

The Parathyroid Hormone (PTH 1-84) group and the comparison group ran side by side rather than switching.

What Was Measured

Topics PubMed links to this paper include Blood Pressure, Blood Pressure Monitoring, Ambulatory, Diastole, Echocardiography, Eplerenone, Hyperparathyroidism, Primary and Hypertension.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in people with hyperparathyroidism.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (Journal of hypertension), a journal based in Netherlands.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.